-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 5, the official website of NMPA showed that Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection, which was produced in the generic category 4, was approved for marketing, which was deemed to have passed the consistency evaluation
.
Palonosetron hydrochloride is the second-generation 5-HT3 receptor antagonist.
In 2020, the sales of Palonosetron injections in public medical institutions in China will exceed 1.
5 billion yuan
.
Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist.
It has a highly selective antagonistic effect on 5-HT3 receptors and can reduce the incidence of nausea and vomiting.
It is currently the only approved for the prevention of delayed onset 5-HT3 receptor antagonist for malignant vomiting
.
Compared with other 5-HT3 antagonists, Palonosetron hydrochloride has the advantages of long half-life and strong affinity with receptors.
It is a commonly used drug for clinical prevention of nausea and vomiting caused by chemotherapy
.
The sales situation of Palonosetron injections in China's public medical institutions (unit: 10,000 yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
According to data from Mynet, urban public hospitals, county-level public hospitals, and urban community centers in China in 2020 And the sales of Palonosetron injection at the terminal of the township health center (referred to as the Chinese public medical institution) exceeded 1.
5 billion yuan, and its sales in 2021H1 exceeded 800 million yuan, a year-on-year increase of 23.
42%
.
It is worth mentioning that on May 24 this year, Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection was approved for listing in the UK
.
Since the beginning of this year, Huiyu Pharmaceutical has approved 4 injections in China, including oxaliplatin injection, bendamustine hydrochloride for injection, irinotecan hydrochloride injection and palonosetron hydrochloride injection
.
The source of the reviewed varieties of Huiyu Pharmaceuticals: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Huiyu Pharmaceuticals has 8 injections approved for production and deemed to have been reviewed, including pemetrexed disodium for injection and doxyl Three varieties of methamphetamine injection and azacitidine for injection were the first to be reviewed
.
Data source: Mi Neiwang database
.
Palonosetron hydrochloride is the second-generation 5-HT3 receptor antagonist.
In 2020, the sales of Palonosetron injections in public medical institutions in China will exceed 1.
5 billion yuan
.
Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist.
It has a highly selective antagonistic effect on 5-HT3 receptors and can reduce the incidence of nausea and vomiting.
It is currently the only approved for the prevention of delayed onset 5-HT3 receptor antagonist for malignant vomiting
.
Compared with other 5-HT3 antagonists, Palonosetron hydrochloride has the advantages of long half-life and strong affinity with receptors.
It is a commonly used drug for clinical prevention of nausea and vomiting caused by chemotherapy
.
The sales situation of Palonosetron injections in China's public medical institutions (unit: 10,000 yuan) Source: Mynet.
com China's public medical institutions' terminal competition pattern.
According to data from Mynet, urban public hospitals, county-level public hospitals, and urban community centers in China in 2020 And the sales of Palonosetron injection at the terminal of the township health center (referred to as the Chinese public medical institution) exceeded 1.
5 billion yuan, and its sales in 2021H1 exceeded 800 million yuan, a year-on-year increase of 23.
42%
.
It is worth mentioning that on May 24 this year, Huiyu Pharmaceutical's Palonosetron Hydrochloride Injection was approved for listing in the UK
.
Since the beginning of this year, Huiyu Pharmaceutical has approved 4 injections in China, including oxaliplatin injection, bendamustine hydrochloride for injection, irinotecan hydrochloride injection and palonosetron hydrochloride injection
.
The source of the reviewed varieties of Huiyu Pharmaceuticals: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, Huiyu Pharmaceuticals has 8 injections approved for production and deemed to have been reviewed, including pemetrexed disodium for injection and doxyl Three varieties of methamphetamine injection and azacitidine for injection were the first to be reviewed
.
Data source: Mi Neiwang database
